Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BG et al. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. doi: 10.1016/S0140-6736(16)31594-X. [Epub ahead of print].
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Gentile M et al. Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24621. [Epub ahead of print].
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.
Nadiminti K et al. Onco Targets Ther. 2017 Jan 6;10:217-226. doi: 10.2147/OTT.S112423. eCollection 2017.
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14465. [Epub ahead of print].
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
Gay F et al. Leukemia. 2017 Jan 24. doi: 10.1038/leu.2016.381. [Epub ahead of print].
Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC et al. Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30.
Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.
Huang LW et al. Hematol Oncol. 2017 Jan 19. doi: 10.1002/hon.2379. [Epub ahead of print].
Modified-CVAD And Modified-CBAD Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma.
Gettys SC et al. Eur J Haematol. 2016 Dec 23. doi: 10.1111/ejh.12843. [Epub ahead of print].
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N et al. Ann Hematol. 2016 Dec 24. doi: 10.1007/s00277-016-2897-2. [Epub ahead of print].
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
Jimenez-Zepeda VH et al. Ann Hematol. 2017 Jan 10. doi: 10.1007/s00277-016-2901-x. [Epub ahead of print].
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Zuo W et al. Medicine (Baltimore). 2017 Jan;96(1):e5787. doi: 10.1097/MD.0000000000005787.
Bortezomib and thalidomide maintenance after stem-cell transplantation for multiple myeloma: A PETHEMA/GEM trial.
Rosiñol L et al. Leukemia. 2017 Jan 23. doi: 10.1038/leu.2017.35. [Epub ahead of print].
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ et al. Leukemia. 2016 Dec 27. doi: 10.1038/leu.2016.390. [Epub ahead of print].
Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
Hu B et al. Int J Clin Pharmacol Ther. 2017 Jan 12. doi: 10.5414/CP202714. [Epub ahead of print].